Stocktoria
Monopar Therapeutics MNPR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-12-19
Chart by TradingView
1/9
Piotroski F — financial health
53.62
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2025 | FY2025 | FY2025 | FY2024 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$16.7M | — | — | — | -$16.2M |
| Net income | -$13.7M | — | — | — | -$15.6M |
| Operating cash flow | -$12.2M | — | — | — | -$6.4M |
| Total assets | $140.7M | $144.2M | $53.9M | $55.1M | $60.3M |
| Total liabilities | $2.9M | $2.6M | $1.7M | $1.5M | $5.3M |
| Shareholders' equity | $137.8M | $141.6M | $52.2M | $53.6M | $55.0M |
| Ratios | |||||
| Return on assets | -9.7% | — | — | — | -25.9% |
| Return on equity | -10.0% | — | — | — | -28.3% |
| Current ratio | 51.35 | 56.10 | 33.94 | — | 11.47 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 53.62 (safe)
- Working capital / assets 0.979
- Retained earnings / assets -0.636
- EBIT / assets -0.119
- Equity / liabilities 47.689
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001645469 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.